KYMR
KYMR
NASDAQ · Biotechnology

Kymera Therapeutics Inc

$104.53
-0.96 (-0.91%)
Analyst Consensus
Strong Buy
29
Analysts
High
Coverage
Buy 27 93%
Hold 2 7%
Sell 0 0%
Price Target
Analyst Price Target -70.3% upside
Low Target $20.33
Average Target $31.03
High Target $33.62
Current Price $104.53
Current
$104.53
Target
$31.03
$20.33 $31.03 avg $33.62
Scenario Analysis
Bear Case
$20.33
-80.6%
Low target
Base Case
$31.03
-70.3%
Avg target
Bull Case
$33.62
+-67.8%
High target
Risk/Reward
0.8x
Unfavorable
Price in Context
52-Week High
$130.05
-19.6% from high
52-Week Low
$36.65
+185.2% from low
50-Day SMA
$78.66
+32.9% vs SMA
200-Day SMA
$56.03
+86.6% vs SMA
RSI (14)
77.3
Overbought
Target vs 52W High
$31.03
-76.1% vs high
Next Earnings Report
Aug 10, 2026
2d
until earnings
EPS Est: $-0.73
Earnings in 2 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 79% $257.58 +5.4%
AMGN
Amgen Inc
Hold 43 49% $190.87 -52.7%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +179.1%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 40 83% $438.34 -9.5%
REGN
Regeneron Pharmaceuticals
Buy 38 71% $76.80 -90.0%
RVMD
Revolution Medicines Inc
Strong Buy 29 93% $114.11 -42.1%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -46.0%
BIIB
Biogen Inc
Buy 44 64% $91.45 -55.7%